JP7445895B2 - 呼吸器合胞体ウイルスｇタンパク質中央保存領域の立体構造エピトープ - Google Patents

呼吸器合胞体ウイルスｇタンパク質中央保存領域の立体構造エピトープ Download PDF

Info

Publication number
JP7445895B2
JP7445895B2 JP2020520775A JP2020520775A JP7445895B2 JP 7445895 B2 JP7445895 B2 JP 7445895B2 JP 2020520775 A JP2020520775 A JP 2020520775A JP 2020520775 A JP2020520775 A JP 2020520775A JP 7445895 B2 JP7445895 B2 JP 7445895B2
Authority
JP
Japan
Prior art keywords
amino acid
protein
rsv
seq
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020520775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536934A5 (enExample
JP2020536934A (ja
Inventor
レベッカ デュボワ
スタッス フェデクキン
ローレンス エム． カウヴァー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of JP2020536934A publication Critical patent/JP2020536934A/ja
Publication of JP2020536934A5 publication Critical patent/JP2020536934A5/ja
Application granted granted Critical
Publication of JP7445895B2 publication Critical patent/JP7445895B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18533—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020520775A 2017-10-13 2018-10-12 呼吸器合胞体ウイルスｇタンパク質中央保存領域の立体構造エピトープ Active JP7445895B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762572271P 2017-10-13 2017-10-13
US62/572,271 2017-10-13
US201762588022P 2017-11-17 2017-11-17
US62/588,022 2017-11-17
US201862633999P 2018-02-22 2018-02-22
US62/633,999 2018-02-22
PCT/US2018/055711 WO2019075400A1 (en) 2017-10-13 2018-10-12 CONFORMATIONAL EPITOPES IN A CENTRAL PROTECTED REGION OF SYNCYTIAL RESPIRATORY VIRUS PROTEIN G

Publications (3)

Publication Number Publication Date
JP2020536934A JP2020536934A (ja) 2020-12-17
JP2020536934A5 JP2020536934A5 (enExample) 2021-12-09
JP7445895B2 true JP7445895B2 (ja) 2024-03-08

Family

ID=66101661

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020520775A Active JP7445895B2 (ja) 2017-10-13 2018-10-12 呼吸器合胞体ウイルスｇタンパク質中央保存領域の立体構造エピトープ

Country Status (6)

Country Link
US (2) US11773143B2 (enExample)
EP (1) EP3694548A4 (enExample)
JP (1) JP7445895B2 (enExample)
AU (1) AU2018346960A1 (enExample)
CA (1) CA3079604A1 (enExample)
WO (1) WO2019075400A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020033742A1 (en) 2018-08-08 2020-02-13 Trellis Bioscience, Llc Improved rsv passive and active vaccines
US12367329B1 (en) * 2024-06-06 2025-07-22 EvolutionaryScale, PBC Protein binder search
CN119479801A (zh) * 2024-11-11 2025-02-18 苏州系统医学研究所 一种针对囊膜病毒表面抗原稳定突变位点的数据预测方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000512136A (ja) 1996-06-05 2000-09-19 バイオモレキュラー・リサーチ・インスティテュート・リミテッド 呼吸器合胞体ウイルスのｇタンパク質と構造的ホモロジーを有するウイルス性ペプチド
US20040009177A1 (en) 2000-10-18 2004-01-15 Tripp Ralph A. Compositions and methods for modulating RSV infection and immunity
JP2007505033A (ja) 2003-07-15 2007-03-08 アイディー バイオメディカル コーポレイション オブ ケベック 呼吸器合胞体得ウイルス感染に対するサブユニットワクチン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0819210A2 (pt) * 2007-10-25 2015-06-23 Trellis Bioscience Inc Anticorpos de proteína g anti-rsv
CN106008716B (zh) 2010-07-07 2019-08-13 人工细胞科技公司 呼吸道合胞病毒抗原组合物和方法
EP3408284A4 (en) * 2016-01-28 2019-08-14 The Brigham and Women's Hospital, Inc. DETERMINATION OF AN ANTIBODY AGAINST A PATHOGEN

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000512136A (ja) 1996-06-05 2000-09-19 バイオモレキュラー・リサーチ・インスティテュート・リミテッド 呼吸器合胞体ウイルスのｇタンパク質と構造的ホモロジーを有するウイルス性ペプチド
US20040009177A1 (en) 2000-10-18 2004-01-15 Tripp Ralph A. Compositions and methods for modulating RSV infection and immunity
JP2007505033A (ja) 2003-07-15 2007-03-08 アイディー バイオメディカル コーポレイション オブ ケベック 呼吸器合胞体得ウイルス感染に対するサブユニットワクチン

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF VIROLOGY，2010年，84(2)，1148-1157
Vaccines，2015年，3，829-849

Also Published As

Publication number Publication date
US11773143B2 (en) 2023-10-03
AU2018346960A1 (en) 2020-05-28
EP3694548A1 (en) 2020-08-19
CA3079604A1 (en) 2019-04-18
US20240150414A1 (en) 2024-05-09
JP2020536934A (ja) 2020-12-17
US20190135876A1 (en) 2019-05-09
WO2019075400A1 (en) 2019-04-18
EP3694548A4 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
CN103483421B (zh) 用于治疗hbv感染及相关疾病的多肽及抗体
WO2021196268A1 (zh) 针对冠状病毒的具有中和活性的抗体及其用途
US20240150414A1 (en) Conformational epitopes in respiratory syncytial virus g protein central conserved region
CN105669838B (zh) 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体
CN103483447B (zh) 抗hpv l1蛋白的广谱单克隆抗体或其抗原结合片段及它们的用途
JP7747353B2 (ja) 抗コロナウイルス完全ヒト広域スペクトル中和抗体７６ｅ１及びその適用
US9902765B2 (en) Antibodies against chikungunya virus and uses thereof
JP7463366B2 (ja) 新規の抗ジカウイルス抗体及びその使用
ES3012638T3 (en) Antibodies capable of binding to the spike protein of coronavirus sars-cov-2
WO2018022786A1 (en) Antibodies to zika virus and methods of use thereof
ES2665851T3 (es) Nuevo anticuerpo anti-CTGF humano
WO2016173559A1 (zh) 抗诺如病毒gi.1型鼠源单克隆抗体的制备和应用
Isaacs et al. A nanobody-based therapeutic targeting Nipah virus limits viral escape
De Cae et al. Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base
WO2022210830A1 (ja) 抗ＳＡＲＳ－ＣｏＶ－２抗体
JP2002020399A (ja) ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
US20240285753A1 (en) Epitope-scaffold immunogens for pancoronavirus vaccines
US20250296987A1 (en) Rsv/hmpv cross-reactive antibodies
US12246063B2 (en) Immunogen providing an extended protective lifetime against respiratory syncytial virus (RSV) and vaccines thereof
US20250179152A1 (en) Sars-cov-2 neutralizing synthetic proteins
Fedechkin Structures Of Respiratory Syncytial Virus G Antigen Bound To Broadly Neutralizing Antibodies For Vaccine And Therapeutic Design

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200414

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200629

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200615

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200630

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210312

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211029

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240215

R150 Certificate of patent or registration of utility model

Ref document number: 7445895

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150